CMSC 2019

Study evaluates the benefits of ocrelizumab on 48-week confirmed disability progression in MS observed in pooled OPERA I and OPERA II, as well as a 3 year ocrelizumab treatment in an open-label extension.

The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.

Investigators sought to determine the safety and efficacy of twice-daily dosing of arbaclofen ER in patients with spasticity due to multiple sclerosis.

Individuals with multiple sclerosis undergoing dimethyl fumarate therapy may be vulnerable to herpes simplex encephalitis.

Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.

Despite the occurrence of thyroid adverse events or their severity, AEs had a minimal impact on quality of life for patients with relapsing-remitting multiple sclerosis who had been treated with alemtuzumab.

Investigators hypothesize siponimod will function as an alternative therapeutic choice to monoclonal antibodies in MS.

Investigators examine the use treatment patterns and utilization of disease-modifying therapy in newly diagnosed pediatric patients with multiple sclerosis.

Initiation of treatment modalities with high efficacy in patients with multiple sclerosis may have a favorable outcome on depressive symptoms.

The investigators of this study sought to evaluate the long-term efficacy and safety of alemtuzumab to treat patients of African descent who have relapsing-remitting MS.